Drugs / Colistimethate
Colistimethate
also known as
colistimethate sodium · CMS · Colistin Methanesulfonate Sodium · Colomycin · Alficetin · CMS-Na · Colimicina · Colimycin · +17 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Colobreathe | — | 2012-02-13 | europa.eu ↗ |
| Approved | US (FDA) | COLY-MYCIN M | — | 1970-06-04 | fda.gov ↗ |
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02156323 | Jul 2014 → Mar 2015 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01863719 | Aug 2013 → May 2017 | pneumococcal infection, pneumonia | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1 | NCT01537614 | Oct 2011 → Feb 2013 | cystic fibrosis | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01449838 | Oct → Dec 2010 | Pseudomonas infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01940731 | Oct 2013 → Mar 2014 | nosocomial infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03460704 | Jan 2018 → Mar 2022 | bronchiectasis | Zambon SpA | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03397914 | Jan 2017 → Jan 2019 | childhood malignant neoplasm, gram-negative bacterial infections | National Cancer Institute, Egypt | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06834971 | Jul 2025 → Sep 2026 expected | — | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| — | NCT02489955 | Feb 2015 → Feb 2017 | cystic fibrosis | The Leeds Teaching Hospitals NHS Trust | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 10 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07512596 Comparator | Jul 2026 → Jul 2027 expected | bacterial pneumonia | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06368804 Background | Sep 2024 → Mar 2025 overdue | bronchiectasis | Centre Hospitalier Intercommunal Creteil | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06488794 Comparator | Jan 2027 → Dec 2028 expected | — | University Hospital Fattouma Bourguiba | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02452047 Comparator | Aug 2015 → Sep 2017 | bacterial infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT07694700 Comparator | Dec 2025 → Aug 2026 overdue | primary bacterial infectious disease | Beni-Suef University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06893835 Comparator | Dec 2024 → May 2025 overdue | primary bacterial infectious disease | Beni-Suef University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06570850 Comparator | Apr 2023 → Mar 2025 overdue | Acinetobacter infectious disease | Chiang Mai University | Recruiting | No outcome recorded |
| Phase 4 | NCT02047773 Comparator | Jan 2014 → Feb 2020 | bronchiectasis | University of Edinburgh | Completed | No outcome recorded |
| Phase 4 | NCT01844778 Comparator | Aug 2013 → Oct 2015 | cystic fibrosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01400750 Comparator | Aug 2001 → Aug 2010 | cystic fibrosis | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Colistimethate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01844778 ↗ |
| Known as | Alficetin | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Known as | CMS | “CMS (colistimethate sodium, 75mg, solubilized in 4 mL 0.9% saline), twice daily.” NCT06834971 ↗ |
| Known as | CMS-Na | “intravenous dosing of Colistin Methanesulfonate Sodium (CMS-Na) in healthy Japanese male subjects.” NCT01449838 ↗ |
| Known as | Colimicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Known as | Colimycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Known as | COLIMYCINE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01537614 ↗ |
| Known as | Colistimetato de sodio | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Known as | Colistimethate sodique | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Known as | colistimethate sodium | “colistimethate sodium (COLI), both administered via nebulizers” PMID 28614995 ↗ Jul 201712“inhaled colistimethate sodium (CMS), administered twice a day” NCT03460704 ↗ “inhaled colistimethate sodium (Colistineb® 2x2 mill U daily)” NCT01400750 ↗ |
| Known as | Colistimethate Sodium for Injection | “Colistimethate Sodium for Injection is a prodrug of polymyxin E. After entering the body, polymyxin E mesylate is hydrolyzed to polymyxin E (colistin), which exerts...” NCT07512596 ↗ |
| Known as | Colistin methanesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Known as | Colistin Methanesulfonate Sodium | “intravenous dosing of Colistin Methanesulfonate Sodium (CMS-Na) in healthy Japanese male subjects.” NCT01449838 ↗1“multiple doses of colistin methanesulfonate sodium (CMS)” NCT02156323 ↗ |
| Known as | Colistin methanesulfonic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Known as | Colistin Sodium Methanesulfonate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06570850 ↗ |
| Known as | Colistin sodium methanesulphonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Known as | Colistin sulfomethate | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Known as | Colistin sulphomethate | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Known as | Colobreathe | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Known as | Colomycin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02489955 ↗ |
| Known as | Coly-mycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Known as | Methacolimycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Known as | NSC-756688 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Known as | Promixin | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Known as | sodium colistimethate | “nebulized sodium colistimethate (1 Million Units tw/d)” NCT06368804 ↗ |
| Known as | W 1929 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067483 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT01449838 ↗ |